Showing 7211-7220 of 8826 results for "".
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Genome-Wide Study Reveals Genetic Correlation Between Melanoma Subtypeshttps://practicaldermatology.com/news/genome-wide-study-reveals-genetic-correlation-between-melanoma-subtypes/2467851/Data from a recent genome-wide association study (GWAS) looking at the genetic underpinnings of in situ and invasive melanoma show significant shared genetic architecture between the two. Researchers for the study used data from four population-based genetic cohorts, including the UK Bio
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Tildrakizumab Shows Efficacy in Plaque Psoriasishttps://practicaldermatology.com/news/tildrakizumab-shows-significant-efficacy-plaque-psoriasis/2467713/Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolle
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ
- ZORYVE Cream 0.15% for AD Commercially Available This Weekhttps://practicaldermatology.com/news/zoryve-cream-015-ad-commercially-available-week/2467570/Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild-to-moderate atopic dermatitis in adults and children down to age 6 in the United States, along with a co-promotion agreement with Kowa Pharmaceuticals America, Inc. ZORYVE is a o
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu